3Stevens D A, Kan V L, Judson M A, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America [J]. Clin Infect Dis, 2000, 30(4) : 696 -709.
4Fischler D F, Hall G S, Gordon S, et al. Aspergillus in cytology specimens: a review of 45 specimens from 36 patients[ J]. Diagn Cytopathol, 1997, 16(1):26-30.
2Ascioglu S, Rex JH, de Pauw B,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus. Clin Infect Dis,2002,34:7-14.
3Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal gents in the treatment of invasive Candida and mould infections. Intern Med J,2004,34:192-200.
4Donnelly JP. A strategy for managing fungal infections in haematopoietic stem cell transplantation. Transpl Infect Dis,2000,2 :88-95.
5Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis,2002,21:161-172.
6Nierman WC, Pain A, Anderson MJ, et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature ,2005,438 : 1151-1156.
7Rementeria A, Lopez-Molina N, Ludwiq A, et al. Genes and molecules involved in Aspergillus fumigatus virulence. Rev Iberoam Micol,2005,22 : 1-23.
8Brakhage AA. Systemic fungal infections caused by Aspergillus species:epidemiology,infection process and virulence determinants. Curr Drug Targets ,2005,6:875-886.
9Lessing F, Kniemeyer O, Wozniok I, et al. The Aspergillus fumigatus transcriptional regulator AfYapl represents the major regulator for defense against reactive oxygen intermediates but is dispensable for pathogenicity in an intranasal mouse infection model. Eukaryot Cell,2007,6:2290-2302.
10Lamarre C, Ibrahim-Granet O, Du C, et al. Characterization of the SKN7 ortholog of Aspergillus fumigatus. Fungal Genet Biol, 2007,44 : 682 -690.
